Discover how deucravacitinib, a first‑in‑class oral TYK2 inhibitor, delivers biologic‑like efficacy in plaque psoriasis with once‑daily dosing, high selectivity, and a potentially improved safety profile compared with traditional JAK inhibitors.
Learn what deucravacitinib is, how selective TYK2 inhibition works, and key clinical trial results in moderate-to-severe plaque psoriasis. Discover its mechanism, benefits over traditional JAK inhibitors, and potential role as an oral alternative to biologics.
Learn what deucravacitinib is, how its selective TYK2 inhibition differs from traditional JAK inhibitors, and why it’s becoming a leading oral treatment option for moderate-to-severe plaque psoriasis based on Phase 3 POETYK PSO clinical trial data.
Learn what deucravacitinib is, how its selective TYK2 allosteric inhibition works, and why it’s reshaping treatment for moderate‑to‑severe plaque psoriasis with biologic‑like efficacy and a differentiated safety profile.
Learn what deucravacitinib is, how its selective TYK2 inhibition differs from traditional JAK inhibitors, and why it’s reshaping treatment for plaque psoriasis and other autoimmune diseases with a potentially improved safety profile.
Learn what deucravacitinib is, how its selective TYK2 allosteric inhibition works, and how it differs from traditional JAK inhibitors in autoimmune diseases like plaque psoriasis, psoriatic arthritis, SLE, and IBD.
Learn what deucravacitinib is, how this first-in-class selective TYK2 inhibitor works, and why it’s changing the treatment landscape for moderate-to-severe plaque psoriasis and other autoimmune diseases, with data from pivotal phase 3 clinical trials.